MX9203444A - Medicamentos. - Google Patents
Medicamentos.Info
- Publication number
- MX9203444A MX9203444A MX9203444A MX9203444A MX9203444A MX 9203444 A MX9203444 A MX 9203444A MX 9203444 A MX9203444 A MX 9203444A MX 9203444 A MX9203444 A MX 9203444A MX 9203444 A MX9203444 A MX 9203444A
- Authority
- MX
- Mexico
- Prior art keywords
- medicines
- agonist
- medicament
- manufacture
- indicated
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919113802A GB9113802D0 (en) | 1991-06-26 | 1991-06-26 | Medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9203444A true MX9203444A (es) | 1993-12-01 |
Family
ID=10697363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9203444A MX9203444A (es) | 1991-06-26 | 1992-06-26 | Medicamentos. |
Country Status (34)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
| GB9226566D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| US5616603A (en) * | 1995-05-26 | 1997-04-01 | Smithkline Beecham Plc | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
| GB9226530D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| US5618948A (en) * | 1995-05-26 | 1997-04-08 | Smithkline Beecham P.L.C. | Process for preparing an enantiomer of a carbazole derivative |
| EP0749962B1 (en) * | 1995-06-23 | 2000-11-02 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles |
| US5917054A (en) * | 1995-07-18 | 1999-06-29 | Smithkline Beecham P.L.C. | Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists |
| US5708187A (en) * | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| GB9723061D0 (en) * | 1997-10-31 | 1998-01-07 | Vanguard Medica Ltd | Medicaments |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| GB9808069D0 (en) * | 1998-04-16 | 1998-06-17 | Vanguard Medica Ltd | Novel processes |
| GB9817911D0 (en) * | 1998-08-17 | 1998-10-14 | Vanguard Medica Ltd | New use |
| US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
| US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
| US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
| AU2002338726B2 (en) * | 2001-09-28 | 2007-03-15 | F. Hoffmann-La Roche Ag | Pseudopolymorphic forms of carvedilol |
| RU2340619C2 (ru) | 2002-06-21 | 2008-12-10 | Сувен Лайф Сайенсиз Лимитед | Новые тетрациклические арилсульфонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции |
| ES2336664T3 (es) | 2002-06-21 | 2010-04-15 | Suven Life Sciences Limited | Arilaquil indoles que tienen afinidad por receptores de serotonina utiles como agentes terapeuticos, procesos para su preparacion y composiciones farmaceuticas que los contienen. |
| AU2003237599B2 (en) | 2002-11-28 | 2009-06-18 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| PT1567492E (pt) | 2002-11-28 | 2013-07-22 | Suven Life Sciences Ltd | N-arilsulfonil-3-aminoalcoxi-indóis |
| KR100739987B1 (ko) | 2002-12-18 | 2007-07-16 | 수벤 라이프 사이언시스 리미티드 | 세로토닌 수용체 친화력을 가지는 테트라사이클릭 3-치환인돌 |
| RU2430088C2 (ru) * | 2004-07-14 | 2011-09-27 | Центарис Гмбх | Производные тетрагидрокарбазола и фармацевтическая композиция на их основе |
| US7601856B2 (en) | 2006-07-27 | 2009-10-13 | Wyeth | Benzofurans as potassium ion channel modulators |
| JP5220013B2 (ja) * | 2006-08-07 | 2013-06-26 | アクテリオン ファーマシューティカルズ リミテッド | （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体 |
| JP2010522135A (ja) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| ES2691033T3 (es) | 2007-02-11 | 2018-11-23 | Map Pharmaceuticals Inc. | Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios |
| US20090069399A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched frovatriptan |
| CA2905541C (en) | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| WO2010073253A1 (en) * | 2008-12-22 | 2010-07-01 | Natco Pharma Limited | Method for preparing an optically active frovatriptan |
| CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| WO2011050140A1 (en) | 2009-10-22 | 2011-04-28 | Blue Fury Consulting, L.L.C. | Posterior cervical fusion system and techniques |
| US10098674B2 (en) | 2009-10-22 | 2018-10-16 | Nuvasive, Inc. | System and method for posterior cervical fusion |
| EP2734634B1 (en) | 2011-07-22 | 2019-08-21 | The University of Chicago | Igf-1 for use in the treatment of migraine |
| CA2895816C (en) | 2012-12-21 | 2021-02-23 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
| EP2816030A1 (en) | 2013-06-20 | 2014-12-24 | Duke Chem, S. A. | Process for the preparation of frovatriptan and its enantiomer |
| GB201312768D0 (en) * | 2013-07-17 | 2013-08-28 | Ge Healthcare Ltd | Work-up procedure |
| US10179109B2 (en) | 2016-03-04 | 2019-01-15 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
| EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
| WO2025038666A2 (en) * | 2023-08-13 | 2025-02-20 | GATC Health Corp | Compounds and methods for treating addiction |
| CN119499195A (zh) * | 2024-11-26 | 2025-02-25 | 青岛国信制药有限公司 | 一种快速吸收琥珀酸呋罗曲坦片及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642816A (en) * | 1967-08-10 | 1972-02-15 | Sterling Drug Inc | 3-acetamido-1 2 3 4-tetrahydrocarbazole |
| US3959309A (en) * | 1968-01-24 | 1976-05-25 | Sterling Drug Inc. | 3-Amido-1,2,3,4-tetrahydrocarbazoles |
| US4062864A (en) * | 1968-01-24 | 1977-12-13 | Sterling Drug Inc. | 3-Hydroxy carbazole derivatives |
| US3592824A (en) * | 1970-03-12 | 1971-07-13 | Miles Lab | 3-substituted amino-1,2,3,4-tetrahydrocarbazoles |
| BE787537A (fr) * | 1971-08-16 | 1973-02-14 | Sterling Drug Inc | Tetrahydrocarbazoles |
| US4172834A (en) | 1971-08-16 | 1979-10-30 | Sterling Drug Inc. | 3-Amino-tetrahydrocarbazoles |
| DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US4257952A (en) * | 1977-06-06 | 1981-03-24 | Sterling Drug Inc. | 3-Amino-tetrahydrocarbazoles |
| US4254134A (en) * | 1978-03-17 | 1981-03-03 | Endo Laboratories, Inc. | Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles |
| EP0115607A1 (de) * | 1983-01-04 | 1984-08-15 | MERCK PATENT GmbH | Tetrahydrocarbazolderivate |
-
1991
- 1991-06-26 GB GB919113802A patent/GB9113802D0/en active Pending
-
1992
- 1992-06-17 SK SK1685-98A patent/SK280907B6/sk not_active IP Right Cessation
- 1992-06-17 CA CA002113726A patent/CA2113726C/en not_active Expired - Lifetime
- 1992-06-17 DK DK92912379T patent/DK0591280T3/da active
- 1992-06-17 KR KR1019930704055A patent/KR100251571B1/ko not_active Expired - Lifetime
- 1992-06-17 UA UA93002251A patent/UA41254C2/uk unknown
- 1992-06-17 WO PCT/GB1992/001082 patent/WO1993000086A1/en active IP Right Grant
- 1992-06-17 SK SK1319-93A patent/SK280905B6/sk not_active IP Right Cessation
- 1992-06-17 DE DE69226953T patent/DE69226953T2/de not_active Expired - Lifetime
- 1992-06-17 CZ CZ961506A patent/CZ282327B6/cs not_active IP Right Cessation
- 1992-06-17 PL PL92301883A patent/PL169392B1/pl unknown
- 1992-06-17 AT AT92912379T patent/ATE170746T1/de active
- 1992-06-17 BR BR9206237A patent/BR9206237A/pt not_active Application Discontinuation
- 1992-06-17 CZ CS932861A patent/CZ282083B6/cs not_active IP Right Cessation
- 1992-06-17 DE DE2002199042 patent/DE10299042I2/de active Active
- 1992-06-17 EP EP92912379A patent/EP0591280B1/en not_active Expired - Lifetime
- 1992-06-17 US US08/167,846 patent/US5464864A/en not_active Expired - Lifetime
- 1992-06-17 SG SG1996004938A patent/SG47877A1/en unknown
- 1992-06-17 PL PL92307118A patent/PL169410B1/pl unknown
- 1992-06-17 PL PL92311304A patent/PL171034B1/pl unknown
- 1992-06-17 RU RU93058534A patent/RU2137474C1/ru active Protection Beyond IP Right Term
- 1992-06-17 HU HU9303731A patent/HU218907B/hu active IP Right Revival
- 1992-06-17 SK SK1054-98A patent/SK280906B6/sk not_active IP Right Cessation
- 1992-06-17 CZ CZ961505A patent/CZ282061B6/cs not_active IP Right Cessation
- 1992-06-17 JP JP51108692A patent/JP3261502B2/ja not_active Expired - Lifetime
- 1992-06-24 NZ NZ243288A patent/NZ243288A/en not_active IP Right Cessation
- 1992-06-24 ZA ZA924658A patent/ZA924658B/xx unknown
- 1992-06-24 PT PT100620A patent/PT100620B/pt not_active IP Right Cessation
- 1992-06-24 MA MA22853A patent/MA22563A1/fr unknown
- 1992-06-25 IL IL117105A patent/IL117105A/en not_active IP Right Cessation
- 1992-06-25 TW TW081104991A patent/TW214544B/zh not_active IP Right Cessation
- 1992-06-25 IL IL117104A patent/IL117104A/xx not_active IP Right Cessation
- 1992-06-25 CN CN92108831A patent/CN1034072C/zh not_active Expired - Lifetime
- 1992-06-25 IL IL11710596A patent/IL117105A0/xx unknown
- 1992-06-25 IL IL102322A patent/IL102322A/xx not_active IP Right Cessation
- 1992-06-25 AP APAP/P/1992/000403A patent/AP344A/en active
- 1992-06-26 SI SI9200125A patent/SI9200125B/sl unknown
- 1992-06-26 MX MX9203444A patent/MX9203444A/es unknown
- 1992-07-01 IE IE206292A patent/IE922062A1/en not_active IP Right Cessation
- 1992-10-04 SA SA92130141A patent/SA92130141B1/ar unknown
-
1993
- 1993-12-23 FI FI935842A patent/FI103967B1/fi not_active IP Right Cessation
- 1993-12-23 NO NO934759A patent/NO304774B1/no not_active IP Right Cessation
-
1995
- 1995-05-15 US US08/442,719 patent/US5637611A/en not_active Expired - Lifetime
-
1997
- 1997-05-06 BR BR1100460-6A patent/BR1100460A/pt active IP Right Grant
-
2002
- 2002-07-24 LU LU90939C patent/LU90939I2/fr unknown
- 2002-10-14 NL NL300103C patent/NL300103I2/nl unknown
-
2005
- 2005-05-03 NO NO2005011C patent/NO2005011I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9203444A (es) | Medicamentos. | |
| ES2552639T3 (es) | Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos | |
| CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
| ES2164040T1 (es) | Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos. | |
| ES2093735T3 (es) | Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica. | |
| ES2037385T3 (es) | Un procedimiento de manufactura de una preparacion farmaceutica para administracion local. | |
| ES2091877T3 (es) | Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia. | |
| ES2159591T3 (es) | Composicion de liberacion controlada. | |
| AR004700A1 (es) | 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento | |
| AR029605A1 (es) | DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS | |
| ES2166111T3 (es) | Uso de tiagabina para el tratamiento de trastornos del sueño. | |
| ES2156840T1 (es) | Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis. | |
| ES2092890T3 (es) | Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson. | |
| AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
| CL2008003941A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo. | |
| CY1107909T1 (el) | Πολυστρωματικο δισκιο περιεχον ροσιγλιταζονη | |
| UY25544A1 (es) | Forma de dosificación de nefazodona | |
| AR026968A1 (es) | Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral | |
| AR024998A1 (es) | Nuevos retinoides para el tratamiento del enfisema | |
| ES2068705T3 (es) | Tratamiento de la enfermedad neoplastica con interleuquina-10. | |
| BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
| ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
| MX9706957A (es) | Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina. | |
| ES2191942T3 (es) | Nueva utilizacion de un antagonista especifico de los receptores 5ht2a. | |
| AR023687A1 (es) | Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa |